Sirnaomic
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Sirnaomics Announces 2023 Annual Results 2024-03-28 17:09
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors 2024-01-24 17:49
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770 2023-12-18 22:04
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment 2023-12-06 01:01
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer 2023-12-01 14:41
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction 2023-11-01 22:07
Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors 2023-08-31 11:30
Sirnaomics Announces 2023 Interim Results 2023-08-31 10:40
Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development 2023-07-28 11:56
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences 2023-07-12 20:45
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company 2023-07-05 23:07
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development 2023-06-19 21:29
Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences 2023-06-14 00:42
Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty 2023-06-05 19:12
Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment 2023-06-02 00:06
Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan 2023-05-17 21:13
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine 2023-04-28 00:29
Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program 2023-04-12 16:25
Sirnaomics Announces 2022 Annual Results 2023-03-28 19:26
Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit 2023-03-20 23:27
1 2 3